Rani Therapeutics Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Für Rani Therapeutics Holdings wird ein Gewinn- und Umsatzwachstum von 6.8% bzw. 65.1% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 6.4% pro Jahr steigen soll.
Wichtige Informationen
6.8%
Wachstumsrate der Gewinne
6.36%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 14.8% |
| Wachstumsrate der Einnahmen | 65.1% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 01 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Jun 17
RANI: Follow-On Offering Will Support Obesity Capsule Trial Progress
Analysts have reaffirmed their $11.00 price target on Rani Therapeutics Holdings, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with prior estimates. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings filed a follow-on equity offering totaling approximately US$20.0 million in Class A common stock and pre-funded warrants, including 12,476,637 Class A shares at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, according to company filings.Narrativ-Update • Jun 02
RANI: Obesity Capsule Trial Progress Will Offset Listing And Leadership Uncertainty
Analysts are keeping their price target for Rani Therapeutics Holdings steady at $11.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that refine rather than materially change their overall view. What's in the News Rani Therapeutics Holdings filed a follow-on equity offering of approximately US$20.0 million, including 12,476,637 shares of Class A common stock at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, with a stated discount of US$0.0642 per security, in a registered direct offering.Narrativ-Update • Apr 27
RANI: Obesity Capsule Trial Progress Will Support Strong Future Upside Potential
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing a balance between slightly adjusted revenue growth, profit margin expectations, and a modestly lower future P/E assumption. Valuation Changes Fair Value: $11.00 remains unchanged, indicating no adjustment to the core valuation estimate.Narrativ-Update • Apr 12
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Analysts maintained their $11.00 price target for Rani Therapeutics Holdings, citing only marginal tweaks in their long term growth and P/E assumptions rather than a change in their overall view of the company. Valuation Changes Fair Value: $11.00 remains unchanged, with no adjustment to the headline valuation figure.
Neues Narrativ • Mar 31
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Catalysts About Rani Therapeutics Holdings Rani Therapeutics Holdings is a clinical stage biotherapeutics company focused on enabling oral delivery of biologic drugs through its RaniPill capsule platform. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Mar 29
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Analysts have kept their price target for Rani Therapeutics Holdings steady at $11.00, reflecting updated assumptions for revenue growth, profit margin, and future P/E that broadly balance each other out in their models. What's in the News Rani Therapeutics started a Phase 1 clinical trial of RT-114, an orally administered RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, for the treatment of obesity (Key Developments).Analyseartikel • Mar 28
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Narrativ-Update • Mar 10
RANI: Obesity Capsule Trial Progress Will Support A More Optimistic Outlook
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing updated assumptions about very large revenue growth expectations, a stronger projected profit margin near 21%, and a higher anticipated future P/E multiple as key drivers within their models. What's in the News Rani Therapeutics started a Phase 1 clinical trial for RT-114, an oral RaniPill capsule containing PG-102, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in obesity treatment (Key Developments).Narrativ-Update • Feb 24
RANI: Obesity Capsule Trial Progress Will Support A Stronger Outlook
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing largely steady assumptions around the discount rate, long-term revenue growth, profit margin, and future P/E as reasons to maintain their existing view. What's in the News Rani Therapeutics and ProGen began a Phase 1 clinical trial for RT-114, an oral RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist, for potential obesity treatment (company announcement).Narrativ-Update • Feb 09
RANI: Obesity Capsule Trial Progress Will Support A Stronger Outlook
Analysts kept their fair value estimate for Rani Therapeutics Holdings steady at US$11.00, citing offsetting tweaks to key assumptions such as a slightly higher discount rate, a modestly different revenue growth outlook, a small adjustment to projected profit margins, and a marginally lower future P/E. What's in the News Rani Therapeutics Holdings started a Phase 1 clinical trial of RT-114, an orally administered RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist being developed for obesity, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in single and multiple dosing.Narrativ-Update • Jan 25
RANI: Obesity Trial Progress And Index Inclusion Will Support A Stronger Outlook
Analysts have kept their US$11.00 price target for Rani Therapeutics Holdings unchanged, citing only fine tuned inputs in discount rate, revenue growth, profit margin and future P/E assumptions that collectively do not shift their overall valuation view. What's in the News Rani Therapeutics and ProGen began a Phase 1 clinical trial of RT-114, an oral RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in obesity treatment (Key Developments).Narrativ-Update • Jan 11
RANI: Future Obesity Trial Progress Will Support A Stronger Bullish Outlook
Analysts have raised their fair value estimate for Rani Therapeutics Holdings from US$9.00 to US$11.00. They cite updated assumptions on revenue growth, profit margin and a higher future P/E multiple as the main factors behind the new price target.
Narrativ-Update • Dec 26
RANI: Collaboration With Chugai And Cash Infusion Will Drive Future Upside
Analysts have nudged their price target for Rani Therapeutics Holdings slightly higher to 9.25 dollars, reflecting modestly improved long term growth and profitability assumptions despite largely unchanged valuation inputs. What's in the News Rani Therapeutics was added to the NASDAQ Biotechnology Index, increasing its visibility among biotech investors (Index Constituent Adds).Narrativ-Update • Dec 11
RANI: Licensing Deal And Capital Raise Will Support Future Platform Upside
Analysts have modestly reaffirmed their outlook on Rani Therapeutics Holdings, keeping the price target effectively unchanged at approximately 9.25 dollars. They continue to view the company’s long term revenue growth and margin profile as supportive of its elevated future valuation multiple.Narrativ-Update • Nov 27
RANI: Recent Licensing Agreement Will Drive Platform Expansion and Revenue Potential
Analysts have lowered their price target for Rani Therapeutics Holdings from $9.50 to $9.25. They cited updated estimates of growth and profit margin impacts on future valuation.Seeking Alpha • Nov 05
Rani Therapeutics: Oral Biologics Vision Still Has Early-Stage Risks
Summary Rani Therapeutics Holdings, Inc. targets a new potential oral delivery of biologic drugs via the RaniPill. This could eventually replace injections and improve patient adherence. Their pipeline has RT-102 (osteoporosis), RT-111 (psoriasis), and RT-114 (obesity with ProGen). Interestingly, RANI anticipates initiating RT-114’s Phase 1 trials during 2H2025. So, their IP remains clearly in the very early stages for now. Still, their partnership with Chugai added much upfront cash payments and up to $175 million milestone payments. Overall, RANI stock still appears somewhat overvalued after the recent equity raises. And their IP is highly speculative. So, I feel a neutral Hold makes sense for now. Read the full article on Seeking AlphaNarrativ-Update • Nov 04
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
Analysts have raised their price target for Rani Therapeutics Holdings from $9.00 to $9.50, citing modest adjustments in future earnings expectations and profit margin outlook. What's in the News Rani Therapeutics Holdings announced it will present preclinical data on its RaniPill capsule at ObesityWeek 2025.Narrativ-Update • Oct 21
Analysts Raise Rani Therapeutics Price Target Following Chugai Deal and Valuation Update
Analysts have increased their price target for Rani Therapeutics Holdings from $7.75 to $9.00. They cite recalibrated growth projections and adjusted profit expectations as key factors behind the change.Narrativ-Update • Aug 15
RT-114 And Pill Technology Will Transform Obesity Treatments
Rani Therapeutics Holdings’ lower future P/E and declining net profit margin highlight reduced growth expectations, which is reflected in the consensus price target holding steady at $7.75. What's in the News Filed a $2.99 million follow-on equity offering via registered direct offering, including Class A common stock and pre-funded warrants at significant discount.
Neues Narrativ • Apr 09
RT-114 And Pill Technology Will Transform Obesity Treatments
RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue.Analyseartikel • Feb 07
Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jul 16
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Mar 20
Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Aug 08
Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development
Rani Therapeutics (NASDAQ:RANI) enters a loan agreement with Avenue Venture Opportunities Fund for up to $45M of funding. This financing is expected to support the continued advancement of the RaniPill platform and ongoing clinical development of the company’s drug pipeline. Under the loan agreement, company will receive $15M of the initial $30M tranche at closing, with the remaining $15M available for draw at the company’s discretion in Q4 2022. Company has the right to request an additional $15M of funds in the future if certain conditions and milestones are met. Interest at a variable rate equal to the greater of (1) prime, plus 5.6% and (2) 10.35%Analyseartikel • Feb 13
We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 12 | -40 | -48 | -33 | 4 |
| 12/31/2027 | 5 | -40 | -46 | -35 | 4 |
| 12/31/2026 | 4 | -33 | -40 | 7 | 4 |
| 3/31/2026 | 3 | -29 | -17 | -17 | N/A |
| 12/31/2025 | 2 | -30 | -19 | -19 | N/A |
| 9/30/2025 | 1 | -28 | -28 | -28 | N/A |
| 6/30/2025 | 1 | -30 | -31 | -31 | N/A |
| 3/31/2025 | 1 | -30 | -35 | -34 | N/A |
| 12/31/2024 | 1 | -30 | -36 | -35 | N/A |
| 9/30/2024 | N/A | -28 | -40 | -39 | N/A |
| 6/30/2024 | N/A | -31 | -46 | -45 | N/A |
| 3/31/2024 | N/A | -33 | -49 | -48 | N/A |
| 12/31/2023 | N/A | -34 | -52 | -51 | N/A |
| 9/30/2023 | N/A | -36 | -55 | -53 | N/A |
| 6/30/2023 | N/A | -34 | -53 | -51 | N/A |
| 3/31/2023 | N/A | -33 | -51 | -49 | N/A |
| 12/31/2022 | N/A | -31 | -48 | -47 | N/A |
| 9/30/2022 | N/A | -27 | -45 | -43 | N/A |
| 6/30/2022 | N/A | -22 | -43 | -42 | N/A |
| 3/31/2022 | 2 | -15 | -38 | -38 | N/A |
| 12/31/2021 | 3 | -8 | -33 | -32 | N/A |
| 9/30/2021 | 3 | -3 | -28 | -27 | N/A |
| 6/30/2021 | 3 | N/A | -16 | -16 | N/A |
| 3/31/2021 | 1 | 5 | -13 | -13 | N/A |
| 12/31/2020 | 0 | N/A | -16 | -15 | N/A |
| 12/31/2019 | 1 | -27 | N/A | -26 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: RANI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: RANI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: RANI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: RANIDie Einnahmen des Unternehmens (65.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (13% pro Jahr).
Hohe Wachstumseinnahmen: RANIDie Einnahmen des Unternehmens (65.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von RANI in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/22 10:14 |
| Aktienkurs zum Tagesende | 2026/06/18 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Rani Therapeutics Holdings, Inc. wird von 9 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Mitchell Kapoor | H.C. Wainwright & Co. |